Study summary

Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Most people with this type of cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab is thought to work by attaching to the Claudin 18.2 protein in their tumor, which switches on the body’s immune system to attack the tumor. There is an unmet medical need to treat people with advanced stomach cancer or GEJ cancer. This study will give more information about how well zolbetuximab works when given with chemotherapy in adults with advanced stomach cancer or GEJ cancer. In this study, adults with advanced stomach cancer or GEJ cancer will either be given zolbetuximab with chemotherapy or a placebo with chemotherapy. A placebo looks like zolbetuximab but doesn’t have any medicine in it. Zolbetuximab with chemotherapy has already been approved to treat gastric cancer and GEJ cancer in some countries. This study is being done in countries where zolbetuximab has not yet been approved for use. If zolbetuximab becomes approved for use in those countries taking part in this study, the study doctor will switch study treatment in those countries to the licensed zolbetuximab. If this happens, people taking part in those countries will leave this study and receive licensed zolbetuximab.

The main aim of the study is to check if zolbetuximab and chemotherapy can prevent or delay the worsening of people’s gastric cancer and GEJ cancer compared to placebo and chemotherapy.

Adults with advanced stomach cancer or GEJ cancer can take part. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. A tumor sample of their cancer will also have the Claudin 18.2 protein. They may have been previously treated with certain standard therapies, but have not been treated with chemotherapy for their cancer. People cannot take part if they need to take medicines to suppress their immune system, have blockages or bleeding in their gut, have specific uncontrollable cancers such as symptomatic or untreated cancers in the nervous system, or have a specific heart condition, or infections.

The study treatments are either zolbetuximab with chemotherapy, or placebo with chemotherapy. People who take part will receive just 1 of the study treatments by chance. Study treatment will be double-blinded. That means that the people in the study and the study doctors will not know who takes which of the study treatments. Study treatment will be given in cycles. The study treatment is given to people slowly through a tube into a vein. This is called an infusion. People will have 4 infusions in 6-week (42-day) cycles as follows:

• Zolbetuximab or placebo – 2 infusions in a cycle.

• Chemotherapy (called modified FOLFOX6 or mFOLFOX6) – 3 infusions in a cycle.

The first infusion is combined with zolbetuximab or placebo on day 1 of each cycle. People may receive zolbetuximab or placebo until their cancer worsens, they cannot tolerate the study treatment, or they need to start another cancer treatment. People will receive mFOLFOX6 for up to 6 months (4 study treatment cycles). After the 6 months people may receive chemotherapy containing folinic acid and fluorouracil instead of mFOLFOX6. People may receive folinic acid and fluorouracil chemotherapy for more than 6 months, or until their cancer worsens, they cannot tolerate the study treatment, or they need to start another cancer treatment. People will visit the clinic on certain days during their study treatment. The study doctors will check if people had any medical problems from taking zolbetuximab or the other study treatments. Also, people in the study will have health checks. On some visits they will have scans to check for any changes in their cancer. People will have the option of giving a tumor sample after their study treatment has finished. People will visit the clinic after they stop their study treatment. People who start treatment with licensed zolbetuximab or mFOLFOX6 outside of this study will not need to visit the clinic. People will be asked about any medical problems and will have a health check. People will visit the clinic at 1 month after they stop their study treatment. People will continue to have scans every 9 or 12 weeks to check for any changes in their cancer. People will have telephone health checks every 3 months. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their study treatment or not.

Additional Study Details

Phase
Phase 3
Product
  • zolbetuximab
  • placebo
  • oxaliplatin
  • folinic acid
  • fluorouracil
  • Type
    Interventional
    Masking
    Double (Participant, Investigator)
    Enrollment number
    565
    Show Additional Study Details

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A study to compare zolbetuximab (IMAB362) and chemotherapy with placebo and chemotherapy in adults with gastric cancer.? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Site JP81007
      Sapporo, Hokkaido, Japan
      Completed
      Site JP81012
      Sunto-gun, Shizuoka, Japan
      Completed
      Oregon Health & Science University
      Portland, OR, United States, 97239
      Completed
      Site DE49007
      Munchen, Bayern, Germany, 81925
      Completed
      Site KR82009
      Suwon-si, Gyeonggido [Kyonggi-do], Republic of Korea, 16247
      Completed
      Site BR55003
      Santo Andre, Sao Paulo, Brazil, 09060-650
      Completed
      Site DE49010
      Dresden, Sachsen, Germany, 01307
      Completed
      Site GB44104
      Dundee, United Kingdom, DD2 4BF
      Withdrawn
      Site DE49017
      Berlin, Berlin, Germany, 12200
      Completed
      Site DE49011
      Berlin, Berlin, Germany, 13353
      Completed
      Site FR33101
      St Herblain, Pays-de-la-Loire, France, 44805
      Completed
      Site BR55017
      Belo Horizonte, Brazil, 30130-090
      Completed
      University of Oklahoma Health Science Center
      Oklahoma City, OK, United States, 73104
      Completed
      Site JP81005
      Fukuoka, Fukuoka, Japan
      Withdrawn
      Toledo Clinic Cancer Center - Toledo
      Toledo, OH, United States, 43623
      Completed
      Site IT39022
      Reggio Emilia, Italy, 42123
      Completed
      Site BE32005
      Brugge, Belgium, 8310
      Completed
      University of Maryland Medical Center(UMMC)Transplant Center
      Baltimore, MD, United States, 21201
      Completed
      Site BR55006
      Lajeado, Rio Grande Do Sul, Brazil, 95900000
      Completed
      Loma Linda University
      Loma Linda, CA, United States, 92354
      Completed
      Site TW88604
      Kaohsiung, Kaohsiung, Taiwan, Province of China, 833
      Completed
      Site BE32011
      Charleroi, Belgium, 6000
      Completed
      Site CO57006
      Medellín, Antioquia, Colombia, 574
      Completed
      Site IT39026
      Terni, Italy, 5100
      Completed
      Site IL97201
      Haifa, Israel, 3109601
      Completed
      Seattle Cancer Care Alliance
      Seattle, WA, United States, 98109
      Completed
      Site DE49019
      Heilbronn, Germany, 74078
      Completed
      Site PL48002
      Brzozow, Podkarpackie, Poland, 36-20
      Completed
      University of California Davis
      Sacramento, CA, United States, 95817
      Completed
      Site CA15002
      Montreal, QC, Canada, H3T 1M5
      Completed
      Site IT39006
      Milano, Italy, 20132
      Completed
      Site KR82003
      Seoul, Republic of Korea, 03080
      Completed
      Site IT39013
      Ancona, Ancona, Italy, 60126
      Completed
      The University of Arizona Medical Center
      Tucson, AZ, United States, 85724
      Completed
      Orlando Health Inc
      Orlando, FL, United States, 32806
      Completed
      Northwestern University Medical Center
      Chicago, IL, United States, 60611
      Completed
      Site BR55005
      Sao Jose do Rio Preto, Sao Paulo, Brazil, 15090-000
      Completed
      Site MX52003
      Distrito Federal, Distrito Federal, Mexico, 06720
      Completed
      Site PE51005
      Lima, Lima, Peru, 15036
      Completed
      Site ES34017
      Madrid, Madrid, Spain, 28033
      Active, not recruiting
      Site KR82007
      Seoul, Republic of Korea, 152-703
      Withdrawn
      Cancer Treatment Centers of America, Phoenix
      Goodyear, AZ, United States, 85338
      Completed
      Site BE32010
      Haine-Saint-Paul, Belgium, 7100
      Completed
      Site DE49012
      Berlin, Berlin, Germany, 13125
      Completed
      Site GB44103
      Cambridge, United Kingdom, CB2 0QQ
      Completed
      Site FR33002
      Paris cedex, Paris, France, 75970
      Completed
      Site DE49015
      Magdeburg, Sachsen-Anhalt, Germany, 39104
      Completed
      Site IT39009
      Cremona, Cremona, Italy, 26100
      Completed
      Site FR33010
      Brest Cedex, Bretagne, France, 29609
      Completed
      Site GB44001
      Manchester, Manchester, United Kingdom, M20 4BX
      Completed
      Site CN86008
      Zhengzhou, China, 450000
      Active, not recruiting
      Site PL48004
      Lublin, Lubuskie, Poland, 20-090
      Withdrawn
      St Lukes Hospital Association of Duluth
      Duluth, MN, United States, 55805
      Completed
      Site IT39003
      Piacenza, Italy, 29100
      Completed
      Site GB44009
      Coventry, United Kingdom, CV2 2DX
      Completed
      Mount Sinai School of Medicine
      New York, NY, United States, 10029-6574
      Completed
      Regions Hospital
      St. Paul, MN, United States, 55101
      Completed
      Stony Brook University Medical Center
      Stony Brook, NY, United States, 11794-9452
      Active, not recruiting
      Site TW88605
      Kwei-Shan, Taoyuan, Taiwan, Province of China, 333
      Completed
      Site GB44102
      Sutton, Surrey, United Kingdom, SM2 5PT
      Completed
      Site BR55010
      Brasília, Distrito Federal, Brazil, 70200-730
      Completed
      Site ES34016
      BARCELONA, Barcelona, Spain, 08025
      Completed
      Site CN86003
      Haerbin, Heilongjiang, China, 150081
      Completed
      Site TW88601
      Taipei, Taiwan, Province of China, 112
      Completed
      Site CL56003
      Providencia, Santiago, Chile, 7500921
      Completed
      Site IT39016
      Padova, Padova, Italy, 35128
      Withdrawn
      Site GB44006
      Edinburgh, Scotland, United Kingdom, EH4 2XU
      Completed
      Site CO57007
      Monteria, Córdoba, Colombia, 230002
      Completed
      Karmanos Cancer Institute
      Detroit, MI, United States, 48201
      Terminated
      Site CL56007
      Valdivia, Chile, 5090000
      Completed
      Site FR33001
      Rennes, Bretagne, France, 35042
      Completed
      Site CN86004
      Hangzhou Shi, Zhejiang, China, 310003
      Completed
      University of Colorado
      Aurora, CO, United States, 80045
      Completed
      Site CO57002
      Medellin, Colombia, 0574
      Completed
      Site JP81008
      Koto-ku, Tokyo, Japan
      Completed
      Site JP81010
      Kitaadachi-gun, Saitama, Japan
      Completed
      Memorial Sloan Kettering Cancer Center
      Montvale, NJ, United States, 07645
      Completed
      Site FR33009
      Dijon, Bourgogne, France, 21079
      Completed
      Inova Dwight and Martha Schar Cancer Institute
      Fairfax, VA, United States, 22031
      Completed
      Site ES34013
      Badalona, Barcelona, Spain, 08028
      Completed
      Site JP81009
      Nagoya, Aichi, Japan
      Terminated
      Cancer Treatment Centers of America, Philadelphia
      Philadelphia, PA, United States, 19124
      Completed
      Site BR55002
      Itajai, Santa Catarina, Brazil, 88301-220
      Completed
      Site DE49008
      Munich, Bavaria, Germany, 81377
      Completed
      Site ES34008
      Madrid, Madrid, Spain, 28007
      Completed
      Site JP81003
      Kashiwa, Chiba, Japan
      Completed
      Site CO57001
      Cali, Colombia
      Completed
      Site ES34019
      Burgos, Spain, 09006
      Completed
      Site AU61006
      East Bentleigh, Victoria, Australia, 3165
      Completed
      Site JP81014
      Kobe, Hyogo, Japan
      Withdrawn
      Site IL97208
      Petah-Tikva, Israel, 4941492
      Completed
      University of California - San Francisco
      San Francisco, CA, United States, 94143
      Completed
      Site IL97210
      HaDarom, Israel, 7030000
      Completed
      Precision Cancer Research -Dayton Physicians Network
      Middletown, OH, United States, 45042
      Completed
      Memorial Cancer Institute - West
      Hollywood, FL, United States, 33021
      Completed
      Site CA15008
      Montreal, QC, Canada, H4A 3J1
      Completed
      Site FR33008
      Besancon cedex, Franche-Comte, France, 25033
      Completed
      Site BE32012
      Gent, Oost-Vlaanderen, Belgium, 9000
      Completed
      Site BR55007
      Barretos, São Paulo, Brazil, 14784-400
      Completed
      Site BE32007
      Edegem, Antwerpen, Belgium, 2650
      Completed
      Site JP81004
      Osaka, Osaka, Japan
      Active, not recruiting
      Earle A. Chiles Research Institute
      Portland, OR, United States, 97213
      Completed
      Site CN86006
      Nanjing, Jiangsu, China, 210008
      Completed
      Site DE49004
      Leipzig, Sachsen, Germany, 04103
      Completed
      Site ES34018
      Sevilla, Sevilla, Spain, 41009
      Completed
      Site KR82006
      Seoul, Republic of Korea, 6591
      Completed
      Site GB44008
      Leeds, United Kingdom, LS7 9TF
      Completed
      Site PE51004
      San Isidro, Lima, Peru, L27
      Completed
      Site FR33003
      Lyon, Rhone, France, 69008
      Completed
      Site AU61007
      Kogarah, Australia, 2217
      Active, not recruiting
      Site MX52001
      Aguascalientes, Aguascalientes, Mexico, 20230
      Terminated
      Cancer Treatment Centers of America, Atlanta
      Newman, GA, United States, 30265
      Completed
      Site JP81006
      Chuo-ku, Tokyo, Japan
      Completed
      The University of Texas MD Anderson Cancer Center
      Houston, TX, United States, 77030
      Completed
      Site CN86001
      Xiamen, China
      Active, not recruiting
      Site ES34006
      Zaragoza, Spain, 50009
      Completed
      Site IT39018
      Perugia, Perugia, Italy, 05100
      Completed
      Site TW88607
      Tainan, Taiwan, Province of China, 704
      Completed
      Site BE32001
      Bruxelles, Bruxelles-Capitale, Région de, Belgium, 1200
      Terminated
      Thomas Jefferson University
      Philadelphia, PA, United States, 19107
      Withdrawn
      Site PL48001
      Warszawa, Mazowieckie, Poland, 02-034
      Completed
      Site MX52002
      Mexico, Distrito Federal, Mexico, 06760
      Withdrawn
      Site IT39014
      Bergamo, Italy, 24125
      Completed
      Site KR82008
      Incheon, Republic of Korea, 21556
      Completed
      Site BR55009
      São Paulo, Brazil, 01509-900
      Completed
      Health Partners Institute
      St. Louis Park, MN, United States, 55426
      Completed
      Site BR55015
      Rio de Janeiro, Rio de Janeiro, Brazil, 22793-080
      Completed
      Site IL97203
      Tel Aviv, Israel, 64239
      Completed
      Sanford Cancer Center
      Sioux Falls, SD, United States, 57104
      Completed
      Site PE51003
      Arequipa, Arequipa, Peru, 4001
      Completed
      Site IT39021
      Modena, Modena, Italy, 41124
      Completed
      Site BR55004
      São Paulo, São Paulo, Brazil, 08270-070
      Completed
      Lancaster General Hospital
      Lancaster, PA, United States, 17604
      Completed
      Site CA15005
      Edmonton, AB, Canada, T6G 1Z2
      Completed
      Site JP81002
      Matsuyama, Ehime, Japan
      Completed
      Site IT39024
      Turin TO, Italy, 5-10126
      Completed
      CBCC Global Research, Inc. at Comprehensive Blood and Cancer
      Bakersfield, CA, United States, 93309
      Completed
      Memorial Sloan Kettering Cancer Center
      Commack, NY, United States, 11725
      Completed
      Site IT39019
      Pisa, Pisa, Italy, 56126
      Completed
      Site JP81015
      Hidaka, Saitama, Japan
      Withdrawn
      Gene Upshaw Memorial Tahoe Forest Cancer Center - Pharmacy
      Truckee, CA, United States, 96161
      Completed
      Site IT39020
      Monza, Lombardia, Italy, 20052
      Completed
      Site FR33103
      Creteil, France, 94000
      Terminated
      University of Arizona
      Phoenix, AZ, United States, 85004
      Completed
      Massachusetts General Hospital
      Boston, MA, United States, 02114-2696
      Completed
      Site JP81013
      Bunkyo-ku, Tokyo, Japan
      Completed
      Site CL56008
      Providencia, Chile, 7520378
      Active, not recruiting
      Site MX52004
      Oaxaca, Mexico, Mexico
      Completed
      Site BE32006
      Leuven, Vlaams Brabant, Belgium, 3000
      Completed
      Site TW88603
      Taichung, Taichung, Taiwan, Province of China, 404
      Completed
      Site ES34010
      Avila, Castilla y Leon, Spain, 05004
      Completed
      Site DE49018
      Dresden, Germany, 1067
      Completed
      Site JP81011
      Osaka, Osaka, Japan
      Completed
      Site KR82002
      Seongnam-si, Gyeonggi-do, Republic of Korea, 13620
      Completed
      Site GB44101
      London, London, City of, United Kingdom, SW3 6JJ
      Completed
      Site PL48005
      Wieliszew, Mazowieckie, Poland, 05-135
      Completed
      University of Chicago
      Chicago, IL, United States, 60637
      Completed
      Site JP81001
      Suita, Osaka, Japan
      Completed
      Site AU61011
      Tugun, Queensland, Australia, 4224
      Completed
      Site BE32004
      Brussels, Belgium, 1000
      Completed
      Norton Cancer Institute
      Louisville, KY, United States, 40217
      Completed
      Site CA15009
      Saint-John, NB, Canada, E2L 4L4
      Completed
      Site IT39011
      Meldola, Forli, Italy, 47014
      Completed
      Memorial Sloan Kettering Cancer Center
      Basking Ridge, NJ, United States, 07920
      Completed
      Site PE51001
      Lima, Lima, Peru, L27
      Completed
      Site IT39015
      Roma, Italy, 00128
      Completed
      Site BE32008
      Mons, Hainaut, Belgium, 7000
      Completed
      Memorial Hospital West
      Pembroke Pines, FL, United States, 33028
      Completed
      Site PL48007
      Ostroleka, Mazowieckie, Poland, 07-410
      Completed
      University of Miami
      Miami, FL, United States, 33136
      Completed
      Site IT39012
      Parma, Parma, Italy, 43126
      Completed
      Rhode Island Hospital-Lifespan Cancer Institute
      Providence, RI, United States, 02903
      Completed
      Site IT39004
      Bergamo, Bergamo, Italy, 24127
      Completed
      Dana Farber Cancer Institute
      Boston, MA, United States, 02215
      Completed
      Site AU61002
      Douglas, QLD, Australia, 4814
      Completed
      Site FR33007
      Nice Cedex 2, France, 06189
      Completed
      Beth Israel Deaconess Medical Center
      Boston, MA, United States, 02215
      Completed
      Site FR33006
      Poitiers, Vienne, France, 86021
      Completed
      Site ES34003
      Murcia, Murcia, Spain, 30120
      Completed
      Site CO57005
      Cali, Valle, Colombia
      Completed
      Site FR33011
      Montpellier Cedex 5, Languedoc-Roussillon, France, 34298
      Completed
      Memorial Sloan Kettering Cancer Center
      West Harrison, NY, United States, 10604
      Completed
      Site FR33104
      Saint Priest en Jarez, France, 42270
      Completed
      City of Hope Nat'l Medical Center
      Duarte, CA, United States, 91010
      Completed
      Memorial Sloan Kettering Cancer Center
      Middletown, CT, United States, 07748-3052
      Completed
      Site ES34011
      Alcorcon, Madrid, Spain, 28925
      Completed
      Site TW88606
      Taipei, Taiwan, Province of China, 10002
      Completed
      The Ohio State University Medical Center
      Columbus, OH, United States, 43210
      Completed
      Roswell Park Cancer Institute
      Buffalo, NY, United States, 14263
      Terminated
      The Angeles Clinic and Research Institute
      Los Angeles, CA, United States, 90025
      Completed
      Site GB44004
      London, United Kingdom, W1G 6AD
      Active, not recruiting
      Site ES34004
      Madrid, Madrid, Spain, 28034
      Completed
      Site FR33005
      Nice, Provence-Alpes-Côte-d'Azur, France, 06200
      Completed
      Memorial Sloan Kettering Cancer Center
      Uniondale, NY, United States, 11553
      Completed
      Memorial Sloan Kettering Cancer Center
      New York, NY, United States, 10065
      Completed
      Site IT39008
      Milano, Milano, Italy, 20141
      Completed
      MultiCare Regional Cancer Center - Gig Harbor
      Auburn, WA, United States, 98801
      Completed
      St. Jude Hospital Yorba Linda
      Fullerton, CA, United States, 92835
      Completed
      Site KR82004
      Seoul, Seoul Teugbyeolsi, Republic of Korea, 06351
      Withdrawn
      The Valley Hospital
      Paramus, NJ, United States, 07652
      Completed
      Site IT39023
      Vicenza, VI, Italy, 36100
      Completed
      Site CN86002
      Beijing, China, 100071
      Completed
      Site DE49002
      Mainz, Rheinland-Pfalz, Germany, 55101
      Completed
      Site BR55016
      Passo Fundo, Brazil, 99010-260
      Active, not recruiting
      Site KR82005
      Seoul, Republic of Korea, 05505
      Completed
      Pacific Shores Medical Group
      Huntington Beach, CA, United States, 92648
      Active, not recruiting
      Site ES34005
      Barcelona, Spain, 08003
      Completed
      Site IL97209
      Holon, Israel, 58100
      Completed
      Site IL97202
      Jerusalem, Israel, 91031
      Completed
      Site BE32002
      Bruxelles, Liege, Belgium, 1050
      Completed
      Site GB44003
      Aberdeen, Aberdeenshire, United Kingdom, AB25 2ZN
      Completed
      Site IL97206
      Kfar Saba, HaMerkaz, Israel, 44281
      Completed
      Site CL56005
      Santiago, Chile, 8330032
      Completed
      Site AU61008
      Adelaide, South Australia, Australia, 5011
      Completed
      Site ES34015
      Barcelona, Barcelona, Spain, 08035
      Active, not recruiting
      Site GB44002
      London, United Kingdom, NW1 2PG
      Completed
      Site BR55018
      Santa Catarina, Brazil, 88501-003
      Completed
      Site CN86005
      Hefei, China, 230022
      Completed
      Maryland Oncology Hematology
      Brandywine, MD, United States, 20613
      Completed
      Site PE51006
      Lima, Peru, 15072
      Active, not recruiting
      Site CO57009
      Bogota, DC, Colombia, 110231
      Completed
      Site MX52008
      San Luis de Potosi, Mexico, 78250
      Completed
      Site MX52009
      Jalisco, Mexico, 45030
      Completed
      Site CA15011
      Toronto, ON, Canada, M5G 1X5
      Completed
      Site PL48009
      Warszawa, Poland, 02-781
      Completed
      Site CN86009
      Beijing, China, 100030
      Completed
      Site MX52007
      Ciudad de México, Distrito Federal, Mexico, 3100
      Completed
      Site MX52010
      Veracruz, Ver, Veracruz, Mexico, 91900
      Withdrawn
      Site TW88609
      Tainan, Taiwan, Province of China, 73657
      Completed
      Site TW88608
      Kaohsiung, Taiwan, Province of China, 80756
      Active, not recruiting
      Site DE49021
      Halle, Sachsen-Anhalt, Germany, 06108

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?